{"DataElement":{"publicId":"6384072","version":"1","preferredName":"Acute Leukemia Or Chronic Myelogenous Leukemia Morphologic Response Status","preferredDefinition":"Text term to describe the acute leukemia or chronic myelogenous leukemia disease status based on morphologic evaluation.","longName":"AML_CML_MORP_RESP_STAT","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"3853604","version":"1","preferredName":"Acute Leukemia Or Chronic Myelogenous Leukemia Morphologic Response","preferredDefinition":"A clonal (malignant) hematopoietic disorder affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).  According to the type of blasts present, acute leukemias are classified as acute myeloid leukemia (AML) and precursor lymphoblastic or acute lymphoblastic leukemia (ALL)._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals.  Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and imatinib therapy delay disease progression and prolong overall survival._The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression._A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample._Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"3853602v1.0:3853589v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"3853602","version":"1","preferredName":"Acute Leukemia Or Chronic Myelogenous Leukemia, BCR-ABL1 Positive Response","preferredDefinition":"A clonal (malignant) hematopoietic disorder affecting the bone marrow and the peripheral blood. The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts). According to the type of blasts present, acute leukemias are classified as acute myeloid leukemia (AML) and precursor lymphoblastic or acute lymphoblastic leukemia (ALL).:An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and imatinib therapy delay disease progression and prolong overall survival.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.","longName":"C9300:C37998:C3174:C50995","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Leukemia","conceptCode":"C9300","definition":"A clonal (malignant) hematopoietic disorder with an acute onset, affecting the bone marrow and the peripheral blood.  The malignant cells show minimal differentiation and are called blasts, either myeloid blasts (myeloblasts) or lymphoid blasts (lymphoblasts).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3CAB6C0-9770-2EEB-E040-BB89AD431DF6","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"ONEDATA","dateModified":"2013-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3853589","version":"1","preferredName":"Morphologic Finding Evaluation","preferredDefinition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.:Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","longName":"C35867:C25214","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Finding","conceptCode":"C35867","definition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Evaluation","conceptCode":"C25214","definition":"Systematic, objective appraisal of the significance, effectiveness, and impact of activities or condition according to specified objectives and criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3CB76BD-D0D5-2626-E040-BB89AD436DA7","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"ONEDATA","dateModified":"2013-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E3CAB6C0-977E-2EEB-E040-BB89AD431DF6","latestVersionIndicator":"Yes","beginDate":"2013-08-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-12","modifiedBy":"KNABLEJ","dateModified":"2017-08-23","changeDescription":"8/23/17 jk added registration status and CSI per Round 5 finalization task.  8/13/13 mc Created for CRF Harmonization per request by Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6384032","version":"1","preferredName":"Acute Leukemia/CML Morphologic Finding Response Status","preferredDefinition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample._The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression._A condition or state at a particular time.","longName":"6384032v1.0","context":"Theradex","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"75","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Bone Marrow Response","valueDescription":"Bone Marrow Response","ValueMeaning":{"publicId":"6384035","version":"1","preferredName":"Bone Marrow Response","longName":"6384035","preferredDefinition":"The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.: Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bone Marrow","conceptCode":"C12431","definition":"The tissue occupying the spaces of bone. It consists of blood vessel sinuses and a network of hematopoietic cells which give rise to the red cells, white cells, and megakaryocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C6BAFD-620C-3006-E053-F662850A9BF1","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C6D9E0-063C-32A2-E053-F662850A4499","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"},{"value":"Clinical Benefit","valueDescription":"Clinical Benefit","ValueMeaning":{"publicId":"6384034","version":"1","preferredName":"Clinical Benefit","longName":"6384034","preferredDefinition":"An effect of a therapeutic intervention that prolongs life, improves function, and/or improves the way a subject feels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Benefit","conceptCode":"C142422","definition":"An effect of a therapeutic intervention that prolongs life, improves function, and/or improves the way a subject feels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C6BAFD-61E4-3006-E053-F662850A9BF1","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C6D9E0-0650-32A2-E053-F662850A4499","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"},{"value":"Complete Cytogenetic Remission","valueDescription":"Cytogenetic Complete Response","ValueMeaning":{"publicId":"5508164","version":"1","preferredName":"Cytogenetic Complete Response","longName":"5508164","preferredDefinition":"The disappearance of all signs of cancer, including the absence of a detectable disease-related genetic abnormality, as determined by techniques such as karyotyping or FISH, in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytogenetic Complete Response","conceptCode":"C123578","definition":"The disappearance of all signs of cancer, including the absence of a detectable disease-related genetic abnormality, as determined by techniques such as karyotyping or FISH, in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E4A5C62-66C7-5C40-E053-F662850A331B","latestVersionIndicator":"Yes","beginDate":"2016-10-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-10-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"72C91F6C-AC9C-340D-E053-F662850AB02E","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"ONEDATA","dateModified":"2018-08-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3865327","version":"1","preferredName":"Morphologic Finding Response Status","preferredDefinition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.:The pathologic and/or clinical changes that result from treatment. The changes may refer to eradication of detectable disease, stabilization of disease, or disease progression.:A condition or state at a particular time.","longName":"C35867:C50995:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morphologic Finding","conceptCode":"C35867","definition":"A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease Response","conceptCode":"C50995","definition":"The pathologic and/or clinical changes that result from treatment. The changes may include eradication of detectable disease, stabilization of disease, or disease progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4E2F160-F279-E72E-E040-BB89AD430752","latestVersionIndicator":"Yes","beginDate":"2013-08-26","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-26","modifiedBy":"ONEDATA","dateModified":"2013-08-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NCISTD: NCI CRF Harmonization and Standards Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C6BAFD-61CA-3006-E053-F662850A9BF1","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeDescription":"11/8/18 TT released/PClark.; 8/6/18 Created New from Existing Added PVs 9/29/17 tt Re-added Partial Response PV.  9/28/17 tt versioned VD to remove Partial response (PR) from PVs. 8/23/17 jk added registration status and CSI per Round 5 finalization task.   8/13/13 mc Created for CRF Harmonization per request by Response WG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":" Morphologic Status","type":"Preferred Question Text","description":" Morphologic Status","url":null,"context":"Theradex"}],"origin":"THERADEX:Theradex Systems Inc","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72C6BAFD-62B3-3006-E053-F662850A9BF1","latestVersionIndicator":"Yes","beginDate":"2018-08-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2018-08-06","modifiedBy":"TAYLORT","dateModified":"2018-11-08","changeDescription":"11/8/18 TT released/PClark.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}